References
- Reith DM, Dawson AH, Whyte IM, et al. Relative toxicity of beta blockers in overdose. J Toxicol Clin Toxicol. 1996;34:273–278.
- Love JN, Litovitz TL, Howell JM, et al. Characterization of fatal beta blocker ingestion: a review of the American Association of Poison Control Centers Data from 1985 to 1995. J Toxicol Clin Toxicol. 1997;35:353–359.
- Love JN, Enlow B, Howell JM, et al. Electrocardiographic changes associated with beta-blocker toxicity. Ann Emerg Med. 2002;40:603–610.
- Love JN, Howell JM, Litovitz TL, et al. Acute beta blocker overdose: factors associated with the development of cardiovascular morbidity. J Toxicol Clin Toxicol. 2000;38:275–281.
- Graudins A, Lee HM, Druda D. Calcium channel and beta-blocker antagonist antidotes and adjunct therapies. Br J Clin Pharmacol. 2016;81:453–461.
- Jordo L, Attman PO, Aurell M, et al. Pharmacokinetic and pharmacodynamic properties of metoprolol in patients with impaired renal function. Clin Pharmacokinet. 1980;5:169–180.
- Regardh CG, Jordo L, Ervik M, et al. Pharmacokinetics of metoprolol in patients with hepatic cirrhosis. Clin Pharmacokinet. 1981;6:375–388.
- Bortolotti A, Castelli D, Verotta D, et al. Pharmacokinetic and pharmacodynamic modelling of metoprolol in rabbits with liver failure. Eur J Drug Metab Pharmacokinet. 1989;14:145–151.
- Li P, Robertson TA, Zhang Q, et al. Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. Pharm Res. 2012;29:1658–1669.
- Schulz M, Schmoldt A. Therapeutic and toxic blood concentrations of more than 800 drugs and other xenobiotics. Pharmazie. 2003;58:447–474.
- Page C, Hacket LP, Isbister GK. The use of high-dose insulin-glucose euglycemia in beta-blocker overdose: a case report. J Med Toxicol. 2009;5:139–143.
- Blake CM, Kharasch ED, Schwab M, et al. A meta-analysis of CYP2D6 metabolizer phenotype and metoprolol pharmacokinetics. Clin Pharmacol Ther. 2013;94:394–399.
- Wagner F, Jahnchen E, Trenk D, et al. Severe complications of antianginal drug therapy in a patient identified as a poor metabolizer of metoprolol, propafenone, diltiazem, and sparteine. Klin Wochenschr. 1987;65:1164–1168.
- Bangalore S, Messerli FH, Kostis JB, et al. Cardiovascular protection using beta-blockers: a critical review of the evidence. J Am Coll Cardiol. 2007;50:563–572.